Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Alvotech (NASDAQ: ALVO), a global biotech company, has secured improved terms on its senior secured term loan facility. The company's lenders, including GoldenTree Asset Management, have agreed to reduce interest rates, resulting in estimated savings of $8.2 million in interest payments over the first 12 months.
The facility, which matures in July 2029, will be consolidated into a single tranche with an interest rate of SOFR plus 6.0% per annum, down from previous rates of SOFR plus 6.5% and 10.5%. The total facility balance stands at $1,081 million, with the company maintaining a cash balance of $152 million as of June 25, 2025.
Alvotech (NASDAQ: ALVO) reported strong financial results for H1 2025, highlighted by a 210% year-over-year increase in product revenue to $204.7 million. The company achieved its best quarter ever in operating cash flows and expanded its commercial partnerships.
Key developments include the acquisition of Xbrane's R&D facilities in Sweden and Ivers-Lee Group in Switzerland, strengthening its end-to-end biosimilars platform. The company successfully listed on Nasdaq Stockholm, completed two SDR offerings raising approximately SEK 789 million, and amended its term loan to reduce interest expenses by $8.2 million annually.
Financial highlights include $151.5 million in cash, operating profit of $28.6 million, and net profit of $141.7 million ($0.50 per share). The company also expanded partnerships with Advanz Pharma and Dr. Reddy's Laboratories for multiple biosimilar candidates.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first half 2025 financial results announcement. The company will release its financial results for the period ending June 30, 2025 after U.S. markets close on August 13, 2025.
A conference call and webcast to discuss the results and business highlights will be held on August 14, 2025, at 8:00 am EDT. The presentation will be accessible through Alvotech's investor portal, with a replay available for 90 days following the event.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Linda Jónsdóttir as its new Chief Financial Officer. Linda brings extensive experience from various industries, including a 15-year tenure at Marel where she served in multiple senior roles including CFO and COO. She succeeds Joel Morales, who has served as CFO since 2020 and will transition to an advisory role.
The leadership change comes as Alvotech continues its evolution from a privately held, R&D-focused company to a public, profitable, and fully integrated global commercial biosimilars enterprise. Joel will support the transition period and assist in preparing the company's Q2 results presentation in August.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced the acquisition of Ivers-Lee Group, a Swiss pharmaceutical assembly and packaging services provider. The acquisition integrates Ivers-Lee's operations into Alvotech's Technical Operations division while maintaining it as a separate legal entity.
The strategic move comes as Alvotech prepares to launch three new biosimilars in 2025. Ivers-Lee's GMP-licensed and FDA-approved facility in Burgdorf, Switzerland, along with its unit in Lörrach, Germany, will provide capabilities including assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials. Peter Schüpbach, Ivers-Lee's managing director, will join Alvotech's Technical Operations senior leadership team while continuing to lead Ivers-Lee.
Alvotech (NASDAQ: ALVO) has announced the acquisition of Ivers-Lee Group, a Swiss pharmaceutical assembly and packaging services company. The strategic acquisition integrates Ivers-Lee's operations into Alvotech's Technical Operations division while maintaining it as a separate legal entity.
The acquisition comes as Alvotech prepares to launch three new biosimilars in 2025. Ivers-Lee, founded in 1947, operates from Burgdorf, Switzerland and Lörrach, Germany. Peter Schüpbach, the founder's grandson, will continue as managing director and join Alvotech's Technical Operations leadership team.
The GMP-licensed and FDA-approved Burgdorf facility will provide capabilities including assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials. Ivers-Lee will continue serving existing clients and providing CMO services.
Alvotech S.A. has announced that its treasury holdings have increased significantly, with the company now holding 6.73% of its own shares as of June 25, 2025. This represents 22,484,087 shares out of a total of 334,038,147 shares with voting rights, surpassing the 5% threshold that requires disclosure under Luxembourg transparency laws.
Alvotech (NASDAQ: ALVO) reported strong Q1 2025 financial results, with total revenues reaching $132.8 million, a 260% increase year-over-year. Product revenues surged 786% to $109.9 million, while Adjusted EBITDA improved to $20.5 million from negative $38.4 million in 2023.
The company increased its full-year guidance to $600-$700 million in revenue and $200-280 million in adjusted EBITDA, following the acquisition of Xbrane's R&D operations and rights to a proposed Cimzia biosimilar. Notable achievements include the U.S. launch of SELARSDI™ (ustekinumab-aekn), a Stelara® biosimilar, and BLA filing acceptances for biosimilars to Simponi®, Eylea®, and Prolia/Xgeva.
The company reported a net profit of $109.7 million ($0.39 per share) and expects to be free cash-flow positive in 2025.
Alvotech (ALVO) has announced the granting of stock options to four independent board directors and the vesting of previously awarded Restricted Share Units (RSUs). Each director received options to purchase 24,784 Alvotech shares at an exercise price of $9.28 per share.
The stock options will vest over a three-year period, with one-third vesting each year starting from the grant date of June 25, 2025. Directors must remain board members at the time of vesting to exercise their options. The exercise price was determined by the opening price of Alvotech's ordinary shares on Nasdaq US on the grant date.
Alvotech (NASDAQ: ALVO) has entered into a supply and commercialization agreement with Advanz Pharma for AVT10, a biosimilar candidate to Cimzia® (certolizumab pegol). The agreement focuses on the European market and expands the existing strategic partnership between the two companies.
Notably, Alvotech's biosimilar candidate is currently the only one under development globally referencing Cimzia®, a TNF-alpha inhibitor used for treating chronic rheumatic diseases. The reference product Cimzia® generated worldwide sales of US$2.3 billion in 2024.
This agreement adds to the existing partnership between Alvotech and Advanz Pharma, which already covers biosimilar candidates for more than ten reference biologics. The companies anticipate launching their first biosimilars in Europe in Q4 2025.
FAQ
What is the current stock price of Alvotech (ALVO)?
What is the market cap of Alvotech (ALVO)?
